{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:20:47Z","timestamp":1780320047689,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaceclinicalcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Clinical Case Reports"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.aace.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:01:39Z","timestamp":1686891699000},"page":"136-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Emphysematous Kidney Related to the Use of Empagliflozin in a Diabetic Woman"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0536-1572","authenticated-orcid":false,"given":"Pablo","family":"Echeverria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Saa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis D.","family":"Paz y Mi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.aace.2023.06.001_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.aace.2023.06.001_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.1995.tb07237.x","article-title":"Emphysematous pyelonephritis in diabetic patients","volume":"75","author":"Pontin","year":"1995","journal-title":"Br J Urol"},{"issue":"22","key":"10.1016\/j.aace.2023.06.001_bib3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes,\u00a0and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.aace.2023.06.001_bib4","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.aace.2023.06.001_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.aace.2023.06.001_bib6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"10166","key":"10.1016\/j.aace.2023.06.001_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic\u00a0review and meta-analysis of cardiovascular outcome trials [published\u00a0correction appears in Lancet. 2019 Jan 5;393(10166):30]","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.aace.2023.06.001_bib8","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.aace.2023.06.001_bib9","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"H\u00e4ring","year":"2014","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.aace.2023.06.001_bib10","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.aace.2023.06.001_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.aace.2023.06.001_bib12","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"10.1016\/j.aace.2023.06.001_bib13","first-page":"1801","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.aace.2023.06.001_bib14","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"10.1016\/j.aace.2023.06.001_bib15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.aace.2023.06.001_bib16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.numecd.2016.07.006","article-title":"Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors","volume":"26","author":"Rizzi","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.aace.2023.06.001_bib17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J\u00a0Diabetes Complications"},{"issue":"5","key":"10.1016\/j.aace.2023.06.001_bib18","first-page":"1844","article-title":"Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review","volume":"179","author":"Somani","year":"2008","journal-title":"J\u00a0Urol"},{"issue":"9","key":"10.1016\/j.aace.2023.06.001_bib19","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1464-410X.2010.09660.x","article-title":"Emphysematous pyelonephritis","volume":"107","author":"Ubee","year":"2011","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.aace.2023.06.001_bib20","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1097\/CCM.0000000000005357","article-title":"Executive summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021 [published correction appears in Crit Care Med. 2022 Apr 1;50(4):e413-e414]","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.aace.2023.06.001_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/2230-8210.183475","article-title":"Emphysematous pyelonephritis: A 10-year experience with 26 cases","volume":"20","author":"Misgar","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.aace.2023.06.001_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4103\/UA.UA_17_19","article-title":"Emphysematous pyelonephritis: Does a standard management algorithm and a prognostic scoring model optimize patient outcomes?","volume":"11","author":"Jain","year":"2019","journal-title":"Urol Ann"},{"issue":"1","key":"10.1016\/j.aace.2023.06.001_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008","volume":"36","author":"Dellinger","year":"2008","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.aace.2023.06.001_bib24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000507259","article-title":"Fulminant emphysematous pyelonephritis by Candida glabrata in a kidney allograft","volume":"144","author":"Cases-Corona","year":"2020","journal-title":"Nephron"},{"issue":"1118","key":"10.1016\/j.aace.2023.06.001_bib25","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/postgradmedj-2018-136109","article-title":"Case of acute unilateral emphysematous pyelonephritis and bacteraemia on treatment with canagliflozin","volume":"94","author":"Gupta","year":"2018","journal-title":"Postgrad Med J"},{"issue":"4","key":"10.1016\/j.aace.2023.06.001_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s13730-021-00616-8","article-title":"A\u00a0case of ureteral fungal mass removal in a patient taking empagliflozin","volume":"10","author":"Woloshuk","year":"2021","journal-title":"CEN Case Rep"},{"issue":"1","key":"10.1016\/j.aace.2023.06.001_bib27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/01.ccm.0000626044.43231.80","article-title":"575: Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin","volume":"48","author":"Echeverria","year":"2020","journal-title":"Crit Care Med"}],"container-title":["AACE Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060523001165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060523001165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:32:22Z","timestamp":1762497142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2376060523001165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2376060523001165"],"URL":"https:\/\/doi.org\/10.1016\/j.aace.2023.06.001","relation":{},"ISSN":["2376-0605"],"issn-type":[{"value":"2376-0605","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emphysematous Kidney Related to the Use of Empagliflozin in a Diabetic Woman","name":"articletitle","label":"Article Title"},{"value":"AACE Clinical Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aace.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}